Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ) operates in various business sectors.
Sprint Bioscience AB (publ) (5JA1) - Total Liabilities
Latest total liabilities as of June 2024: €29.61 Million EUR
Based on the latest financial reports, Sprint Bioscience AB (publ) (5JA1) has total liabilities worth €29.61 Million EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sprint Bioscience AB (publ) - Total Liabilities Trend (2018–2023)
This chart illustrates how Sprint Bioscience AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sprint Bioscience AB (publ) Competitors by Total Liabilities
The table below lists competitors of Sprint Bioscience AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MEWAH INTL
BE:MWX
|
Germany | €703.10 Million |
|
Leopard Energy, Inc.
PINK:LEEN
|
USA | $118.35K |
|
TERNIENERGIA
MU:TI5
|
Germany | €209.89 Million |
|
Grom Social Enterprises Inc
NASDAQ:GROM
|
USA | $4.31 Million |
|
Mind Gym Ltd
LSE:MIND
|
UK | GBX8.86 Million |
|
Tavistock Investments Plc
LSE:TAVI
|
UK | GBX12.56 Million |
|
Scoobeez Global Inc
PINK:SCBZ
|
USA | $21.74 Million |
|
Koza Polyester Sanayi ve Ticaret A.S.
IS:KOPOL
|
Turkey | TL2.90 Billion |
Liability Composition Analysis (2018–2023)
This chart breaks down Sprint Bioscience AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sprint Bioscience AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sprint Bioscience AB (publ) (2018–2023)
The table below shows the annual total liabilities of Sprint Bioscience AB (publ) from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €34.60 Million | +274.73% |
| 2022-12-31 | €9.23 Million | +6.35% |
| 2021-12-31 | €8.68 Million | -64.20% |
| 2020-12-31 | €24.25 Million | +194.82% |
| 2019-12-31 | €8.23 Million | -62.68% |
| 2018-12-31 | €22.05 Million | -- |